Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

NCT06510309 is registered in ClinicalTrials.gov with Gottfried von Keudell, MD PhD as lead sponsor.

NCT NCT06510309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06510309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Lead sponsor
Gottfried von Keudell, MD PhD
Phase
Phase 2
Overall status
Recruiting
Start date
February 11, 2026
Completion date
October 1, 2031
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, marginal zone lymphoma, mzl